RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
1-Year Return
18.15%
This Quarter Return
+46.61%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.86B
AUM Growth
+$1.46B
(+23%)
Cap. Flow
+$280M
Cap. Flow
% of AUM
3.56%
Top 10 Holdings %
Top 10 Hldgs %
51.1%
Holding
83
New
21
Increased
18
Reduced
5
Closed
7
Top Buys
| 1 |
Edgewise Therapeutics
EWTX
|
$163M |
| 2 |
Dyne Therapeutics
DYN
|
$141M |
| 3 |
Evolent Health
EVH
|
$105M |
| 4 |
LENZ
LENZ Therapeutics
LENZ
|
$93.3M |
| 5 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$71M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
$704M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$164M |
| 3 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$94M |
| 4 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$93.6M |
| 5 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$73.2M |
Sector Composition
| 1 | Healthcare | 99.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
INBX
26
DELISTED
Inhibrx, Inc. Common Stock
INBX
| $91.9M | 1.17% |
2,629,837
-2,094,370
| -44% | -$73.2M |
|
27
Avidity Biosciences
RNA
$6.12B
| $83.8M | 1.07% |
3,282,180
+827,647
| +34% | +$21.1M |
|
28
Axsome Therapeutics
AXSM
$6.1B
| $79.8M | 1.02% |
1,000,000
| – | – |
|
|
LBPH
29
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $71M | 0.9% |
+3,289,119
| New | +$71M |
|
30
Dianthus Therapeutics
DNTH
$783M
| $70M | 0.89% |
+2,333,000
| New | +$70M |
|
31
GH Research
GHRS
$857M
| $66.6M | 0.85% |
6,251,714
+664,381
| +12% | +$7.08M |
|
32
Structure Therapeutics
GPCR
$1.07B
| $64.7M | 0.82% |
1,510,362
+1,023,530
| +210% | +$43.9M |
|
33
Mineralys Therapeutics
MLYS
$2.03B
| $62.6M | 0.8% |
4,850,984
+1,672,508
| +53% | +$21.6M |
|
34
Astria Therapeutics
ATXS
$381M
| $62.1M | 0.79% |
+4,413,150
| New | +$62.1M |
|
35
CG Oncology
CGON
$2.18B
| $61.3M | 0.78% |
+1,397,433
| New | +$61.3M |
|
36
Acumen Pharmaceuticals
ABOS
$81.8M
| $60.5M | 0.77% |
14,932,063
| – | – |
|
|
ITOS
37
DELISTED
iTeos Therapeutics
ITOS
| $60.3M | 0.77% |
4,417,259
| – | – |
|
38
Solid Biosciences
SLDB
$426M
| $57.7M | 0.73% |
4,330,446
+904,160
| +26% | +$12M |
|
39
Madrigal Pharmaceuticals
MDGL
$9.52B
| $54.6M | 0.69% |
204,500
| – | – |
|
40
Vor Biopharma
VOR
$243M
| $53.9M | 0.69% |
22,748,880
| – | – |
|
41
Praxis Precision Medicines
PRAX
$963M
| $50.5M | 0.64% |
+828,380
| New | +$50.5M |
|
42
UroGen Pharma
URGN
$890M
| $46.3M | 0.59% |
3,083,430
| – | – |
|
43
Larimar Therapeutics
LRMR
$323M
| $45.9M | 0.58% |
+6,045,351
| New | +$45.9M |
|
44
Cytek Biosciences
CTKB
$505M
| $45.7M | 0.58% |
6,809,404
| – | – |
|
45
C4 Therapeutics
CCCC
$185M
| $39.9M | 0.51% |
4,878,000
| – | – |
|
46
Werewolf Therapeutics
HOWL
$60.4M
| $39.8M | 0.51% |
6,144,881
| – | – |
|
47
Enliven Therapeutics
ELVN
$1.2B
| $37.3M | 0.48% |
2,122,465
| – | – |
|
|
CLYM
48
Climb Bio, Inc. Common Stock
CLYM
$157M
| $36M | 0.46% |
13,150,849
| – | – |
|
49
Acrivon Therapeutics
ACRV
$41.5M
| $34.4M | 0.44% |
4,810,508
| – | – |
|
50
Taysha Gene Therapies
TSHA
$865M
| $31.2M | 0.4% |
10,872,503
-7,600,000
| -41% | -$21.8M |
|